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Background
In the treatment of pelvis cancer such as rectum, bladder,
prostate, cervix and others, the use of radiation therapy as
primary or adjuvant cancer treatment is a common prac-
tice; however, complications and side effects could occur,
the most common urological complication present in
about 5.7 to 11.5% of the cases is the post radiation hem-
orrhagic cystitis (PRHC). We present the clinical evolution
of all the patients with PRHC who did not respond to the
standard management of the hemorrhagic cystitis.
Materials and methods
From January 2006 to August 2006, thirty seven patients
with diagnosis of PRHC were evaluated including: sex,
age, oncology diagnostic cystoscopic findings, clinical fea-
tures, blood transfusion required, and failure to treat-
ment, alternative treatment and clinical evolution.
Results
In a period of 8 months, 37 patients from the urology
department of the Instituto Nacional de Cancerología,
were evaluated, 36 female and 1 male, median age 62
years old (43 – 72 years), diagnosis of cervix cancer stage
IIb and IIIb in the females and prostate cancer in the male,
all of them treated with radiotherapy as primary therapeu-
tic technique. The main symptoms were: pelvis pain in 34
cases, dysuria in 25 and gross hematuria in 37, all the
patients underwent cystoscopic evaluation, which
develop inflammatory changes and hemorrhagic lesions
in bladder walls in 100% of the patients. All the cases were
treated with 50 cc intravesical instillations of 50% solu-
tion of dimethylsulfoxide (DMSO) in saline solution
weekly for 6 weeks.
Four cases presented therapeutic failure with gross hema-
turia and required prolonged hospitalization and blood
transfusion of 3 units. The 4 cases were treated with uri-
nary diversion only (ileal conduct) in 3 and urinary diver-
sion and cystectomy in the other. One female treated only
with urinary diversion due to intense desmoplasic reac-
tion secondary to RT which makes cystectomy not possi-
ble, presented persistent hematuria and must be treated
with instillation of 10% of formaldehyde solution under
IV sedation. The evolution was satisfactory after the proce-
dure and the hematuria stopped.
Conclusion
The PRHC must be treated according with the standard
procedures however, the surgical management must be
considered as the definitive procedure in patients with no
response to the intra-vesical therapy.
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